How Do Long-Term Heart Failure Patients Differ from Recently-Diagnosed?

by U.S. Medicine

July 28, 2017

DURHAM, NC – How are long-term chronic heart failure (HF) survivors who are hospitalized for acute exacerbation different from patients with more recent HF diagnoses?

A study led by Duke University and involving researchers from the San Francisco VAMC sought to answer that question, evaluating the influence of HF chronicity on acute HF patient profiles and outcomes. The results were published recently in the Journal of the American College of Cardiology.1

The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hospitalized patients with acute HF with reduced or preserved ejection fraction (EF) to receive nesiritide or placebo in addition to standard care.

Researchers compared patients according to duration of HF diagnosis before index hospitalization by using pre-specified cutoffs — 0 to 1 month was defined as “recently diagnosed,” and the other groups were less than one month to a year, more than a year to 60 months and greater than 60 months.

As a whole, 80.4% of the 5,741patients had documentation of duration of HF diagnosis, with the average age ranging 64 to 66 years, and mean ejection fraction varying from 29% to 32%.

Results indicate that, compared with patients with longer HF duration, recently diagnosed patients were more likely to be women with non-ischemic HF etiology, higher baseline blood pressure, better baseline renal function, and fewer comorbidities.

After adjustment, compared with recently diagnosed patients, patients with longer HF duration were associated with more persistent dyspnea at 24 hours and increased 180-day mortality:

  • 1 to 12 months, odds ratio [OR]: 1.20 and hazard ratio [HR]: 1.89, respectively;
  • >12 to 60 months, OR: 1.34 and HR: 1.82, respectively;
  • >60 months, OR: 1.31 and HR 2.02, respectively.

“The influence of HF duration on mortality was potentially more pronounced among female patients (interaction p = 0.05), but did not differ according to age, race, prior ischemic heart disease, or ejection fraction (all interactions, p ≥ 0.23),” the authors noted.

They concluded, “In this acute HF trial, patient profile differed according to duration of the HF diagnosis. A diagnosis of HF for ≤1 month before hospitalization was independently associated with greater early dyspnea relief and improved post-discharge survival compared to patients with chronic HF diagnoses. The distinction between de novo or recently diagnosed HF and worsening chronic HF should be considered in the design of future acute HF trials.”

  1. Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O’Connor CM, Mentz RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043. PubMed PMID: 28641792.

Related Articles

VA Research Determines Which Beta Blocker Is Better in Heart Failure

ST. LOUIS—Current clinical guidelines recommend the use of beta blockers in all heart failure patients with with reduced ejection fraction (HFrEF). Which beta blocker to use—carvedilol or metoprolol succinate—remained unclear, however, according to a recent... View Article

New VA Analysis Refutes Link Between Heart Failure, Incident Cancer

With about 350,000 patients with heart failure diagnoses being treated in the VHA, recent studies suggesting that the cardiovascular condition increases risk of cancer have been worrisome.

U.S. Medicine Recommends

More From cardiovascular disease

Cardiovascular Disease

Better Sleep Metrics Can Identify CVD Risk in Sleep Apnea

STATESBORO, GA—What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)? A retrospective cohort descriptive study used administrative data from the TRICARE program... View Article

Cardiovascular Disease

Previous VA Research Borne Out: PCI Provides No Symptom Relief in Stable Angina

In a move that reanimated a long-standing controversy in cardiology, a recently published study supports and extends the findings of landmark research done by the VA more than a decade ago.

Cardiovascular Disease

INVESTED Trial Tests High-Dose Flu Vaccine for Veterans With Cardiovascular Disease

Influenza hits veterans hard, and older veterans with cardiovascular disease face a substantially increased risk of complications and death from the common ailment.

Cardiovascular Disease

Is Aspirin Really a Wonder Drug for Cardiovascular Prevention?

Since the mid-1980s, aspirin has been used as a preventive drug for cardiovascular disease. In fact, the U.S. Preventive Services Task Force (USPSTF) says that about 40% of American adults over 50 currently take a daily aspirin to prevent heart attacks or strokes.


Aggressive Therapy Doesn’t Always Lower Heart Rate in Heart Failure

STATESBORO, GA—What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)? A retrospective cohort descriptive study used administrative data from the TRICARE program... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up